Skip to main content

Table 1 Demographic details a

From: Expression of one important chaperone protein, heat shock protein 27, in neurodegenerative diseases

Group (n) M/F,n(missing data) Age at death, yr (mean ± SD) Sections available,n
Frontal Temporal Hippocampal
Controls (32) 14/18 72.0 ± 21.0 19 32 31
AD (46) 23/23 72.0 ± 6.0 46 41 41
MND (25) 20/5 64.3 ± 12.0 17 25 24
FTLD (72) 41/31 65.6 ± 9.1 71 66 60
 FTLD-tau (31) 14/14 (3) 67.2 ± 9.6 31 25 25
  MAPT (5) 2/3 62.2 ± 5.4 5 4 4
  Pick (26) 12/11 (3) 68.3 ± 10.1 26 21 21
 FTLD-TDP (41) 26/15 64.7 ± 8.7 40 41 35
  Type A (17) 8/9 68.7 ± 4.2 17 17 14
  Type B (14) 12/2 58.3 ± 9.0 13 14 12
  Type C (10) 6/4 66.5 ± 9.4 10 10 9
  1. aAD, Alzheimer’s disease; FTLD, Frontotemporal lobar degeneration; FTLD-MAPT, Frontotemporal lobar degeneration with mutations in the microtubule-associated protein tau; MND, Motor neuron disease; FTLD-tau Pick, Frontotemporal lobar degeneration tau with Pick bodies; TDP, Transactive response DNA binding protein 43 proteinopathy (subtypes A, B and C according to Mackenzie et al. [16]).